A post-discharge disease management program for patients with COPD positively impacts 90-day readmission rates.
Roflumilast’s benefit-to-harm ratio suggests that it only provides net benefit in patients at high risk of severe exacerbations.
LOTT trial results bring clarity to the role of supplemental oxygen in COPD patients with moderate resting hypoxemia or with isolated exercise desaturation.
Exacerbations of COPD are linked to poor clinical outcomes and high costs. We discuss the multiple pharmacotherapeutic options and how they may be used to prevent exacerbations.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Significant progress has been made in the pathogenesis, diagnostic strategies and treatment of alpha-1 antitrypsin deficiency, yet referral to an experienced center remains key to managing these patients.
Identifying specific and distinctive clinical phenotypes in COPD is beneficial in identifying pathogenetic mechanisms and prognosis of disease, as well as linking to specific therapies.